Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
Metrics to compare | ASBP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipASBPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.3x | −2.7x | −0.5x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | −0.6x | 2.4x | 2.6x | |
Price / LTM Sales | 3,416.7x | 4.8x | 3.2x | |
Upside (Analyst Target) | - | 111.9% | 51.3% | |
Fair Value Upside | Unlock | 6.1% | 8.9% | Unlock |